Aardvark Therapeutics share price logo

Aardvark Therapeutics Share Price

NASDAQ: AARD

Mid Cap

$9.82

-0.68

(-6.48%)

as on

Aardvark Therapeutics Stock Performance

as on November 7, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $9.85
    $10.56
    downward going graph

    -0.31%

    Downside

    7.54%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $4.88
    $19.58
    downward going graph

    50.31%

    Downside

    99.39%

    Upside

    downward going graph

Aardvark Therapeutics share price movements today

Previous Close
$10.50
Open
$10.56
Volume
266.3K
Day's Low - High
$9.85 - $10.56
52 Week Low - High
$4.88 - $19.58

Aardvark Therapeutics Historical Returns

1 Month Return
-43.31 %
3 Month Return
-17.54 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Aardvark Therapeutics Stock Fundamentals & Key Indicators

Check Aardvark Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$284.4M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Aardvark Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aardvark Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Aardvark Therapeutics image
Aardvark Therapeutics
NA$284.4MNANA0.00%
Insmed Incorporated image
Insmed Incorporated
BUY$39.6B470.1%-16.34-264.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$57.4B236.95%1448.531.36%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$105.8B88.96%29.3231.35%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$67.7B11.91%15.4332.13%

Aardvark Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Aardvark Therapeutics Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Aardvark Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
-
0
-
Operating Income
-1
-2
-2
-6
-5
-9
-10
-15
EBITDA
-1
-2
-2
-6
-5
-9
-10
-15
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
Income Before Tax
-2
-2
-2
-5
-4
-8
-9
-14
Income Tax Expense
-
-
-
-
-
-
-
-
Net Income
-2
-2
-2
-5
-4
-8
-9
-14
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Aardvark Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
Gross Profit
0
0
0
Operating Income
-11
-7
-22
EBITDA
-10
-7
-20
Interest Expense
-
-
-
Depreciation
0
0
0
Income Before Tax
-13
-7
-20
Income Tax Expense
-
-
-
Net Income
-13
-7
-20
Net Profit Margin
0.00%
0.00%
0.00%

Aardvark Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-2
-2
-5
-4
-8
-9
-14
Operating Cash Flow
-1
-2
-4
-3
-7
-11
-9
Investing Cash Flow
-
0
0
0
-11
-112
9
Financing Cash Flow
-
-
82
0
-1
88
0
Change in Cash
-1
-2
78
-3
-20
-35
0

Aardvark Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-7
-20
Operating Cash Flow
-5
-18
Investing Cash Flow
-
-11
Financing Cash Flow
-
81
Change in Cash
-5
51

Insights on Aardvark Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, AARD stock has moved down by -39.7%

About Aardvark Therapeutics

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
OrganisationAardvark Therapeutics
Headquarters4370 La Jolla Village Drive, San Diego, CA, United States, 92122
CEODr. Tien-Li Lee M.D.
E-voting on sharesClick here to vote

Key Management of Aardvark Therapeutics

Name

Title

Dr. Bryan Jones Ph.D.

Chief Operating Officer

Dr. Manasi Sinha Jaiman M.D., M.P.H.

Chief Medical Officer

Dr. Timothy J. Kieffer Ph.D.

Chief Scientific Officer

Mr. Christian Zapf J.D.

General Counsel

Dr. Dvorit Samid Ph.D.

Executive Vice President of Medical Affairs

Dr. Zhenhuan Zheng Ph.D.

Chief Research Officer

Dr. Terrie Kellmeyer Ph.D.

Senior Vice President of Regulatory Affairs

Dr. Tien-Li Lee M.D.

CEO, Secretary & Director

Mr. Nelson B. Sun M.B.A.

Chief Financial Officer

Mr. Ron Lewis II, Ph.D.

VP & Head of CMC

FAQs

What is Aardvark Therapeutics share price today?

Aardvark Therapeutics share price today is $9.82 as on at the close of the market. Aardvark Therapeutics share today touched a day high of $10.56 and a low of $9.85.

What is the 52 week high and 52 week low for Aardvark Therapeutics share?

Aardvark Therapeutics share touched a 52 week high of $19.58 on and a 52 week low of $4.88 on . Aardvark Therapeutics stock price today i.e. is closed at $9.82,which is 49.85% down from its 52 week high and 101.23% up from its 52 week low.

What is Aardvark Therapeutics's market capitalisation today?

Aardvark Therapeutics market capitalisation is $0.00T as on .

How to invest in Aardvark Therapeutics Stock (AARD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aardvark Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aardvark Therapeutics Shares that will get you 0.1527 shares as per Aardvark Therapeutics share price of $9.82 per share as on November 7, 2025 at 2:29 am IST.

What is the minimum amount required to buy Aardvark Therapeutics Stock (AARD) from India?

Indian investors can start investing in Aardvark Therapeutics (AARD) shares with as little as ₹88.566 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹885.66 in Aardvark Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Aardvark Therapeutics share’s latest price of $9.82 as on November 7, 2025 at 2:29 am IST, you will get 1.0183 shares of Aardvark Therapeutics. Learn more about fractional shares .